Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 340, Issue 3, 2012, Pages 612-619

  Bordia, Tanuja ^a   McIntosh, J Michael ^b   Quik, Maryka ^a  

^a SRI INTERNATIONAL   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE TRANSPORTER; NICOTINE; NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA6BETA2; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALEPSY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPAMINE BRAIN LEVEL; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; INVOLUNTARY MOVEMENT; LIGHT DARK CYCLE; MALE; MOLECULAR MECHANICS; NONHUMAN; OROFACIAL DYSKINESIA; PRIORITY JOURNAL; RAT; STRIATE CORTEX; TARDIVE DYSKINESIA; TREATMENT DURATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; CATALEPSY; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DYSKINESIA, DRUG-INDUCED; HALOPERIDOL; MALE; MOVEMENT DISORDERS; NICOTINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC;

EID: 84857310869     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.189100     Document Type: Article

References (48)

1. Aia PG, Revuelta GJ, Cloud LJ, and Factor SA (2011) Tardive dyskinesia. Curr Treat Options Neurol 13:231-241.
2. Albuquerque EX, Pereira EF, Alkondon M, and Rogers SW (2009) Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 89:73-120.
3. Andreassen OA, Ferrante RJ, Aamo TO, Beal MF, and Jørgensen HA (2003) Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats. Neuroscience 122:717-725. (Pubitemid 37410293)
4. 125I autoradiography. J Neurosci Methods 32:185-192.
5. Barroso-Chinea P and Bezard E (2010) Basal ganglia circuits underlying the pathophysiology of levodopa-induced dyskinesia. Front Neuroanat 14:131.
6. Bordia T, Campos C, Huang L, and Quik M (2008) Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease. J Pharmacol Exp Ther 327:239-247.
7. Bordia T, Campos C, McIntosh JM, and Quik M (2010) Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitization. J Pharmacol Exp Ther 333:929-938.
8. Cenci MA and Konradi C (2010) Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. Prog Brain Res 183:209-233.
9. Changeux JP (2010) Nicotine addiction and nicotinic receptors: lessons from genetically modified mice. Nat Rev Neurosci 11:389-401.
10. Correll CU, Leucht S, and Kane JM (2004) Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161:414-425. (Pubitemid 38326094)
11. Diehl A, Reinhard I, Schmitt A, Mann K, and Gattaz WF (2009) Does the degree of smoking effect the severity of tardive dyskinesia? A longitudinal clinical trial. Eur Psychiatry 24:33-40.
12. Gershanik OS and Gómez Arévalo GJ (2011) Typical and atypical neuroleptics. Handb Clin Neurol 100:579-599.
13. Gotti C, Clementi F, Fornari A, Gaimarri A, Guiducci S, Manfredi I, Moretti M, Pedrazzi P, Pucci L, and Zoli M (2009) Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem Pharmacol 78:703-711.
14. Huang LZ, Grady SR, and Quik M (2011a) Nicotine reduces L-DOPA-induced dyskinesias by acting at β2*nicotinic receptors. J Pharmacol Exp Ther 338:932-941.
15. Huang LZ, Campos C, Ly J, Ivy Carroll F, and Quik M (2011b) Nicotinic receptor agonists decrease L-DOPA-induced dyskinesias most effectively in moderately lesioned parkinsonian rats. Neuropharmacology 60:861-868.
16. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
17. Kuschinsky K and Hornykiewicz O (1972) Morphine catalepsy in the rat: relation to striatal dopamine metabolism. Eur J Pharmacol 19:119-122.
18. Levinson AJ, Garside S, Rosebush PI, and Mazurek MF (1998) Haloperidol induces persistent down-regulation of tyrosine hydroxylase immunoreactivity in substantia nigra but not ventral tegmental area in the rat. Neuroscience 84:201-211. (Pubitemid 28081537)
19. Madras BK, Miller GM, and Fischman AJ (2005) The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry 57:1397-1409. (Pubitemid 40798561)
20. Marchese G, Casu MA, Bartholini F, Ruiu S, Saba P, Gessa GL, and Pani L (2002) Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to "early onset" vacuous chewing. Eur J Neurosci 15:1187-1196. (Pubitemid 35463619)
21. Matta SG, Balfour DJ, Benowitz NL, Boyd RT, Buccafusco JJ, Caggiula AR, Craig CR, Collins AC, Damaj MI, Donny EC, et al. (2007) Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl) 190:269-319. (Pubitemid 46156883)
22. Mazurek MF, Savedia SM, Bobba RS, Garside S, and Rosebush PI (1998) Persistent loss of tyrosine hydroxylase immunoreactivity in the substantia nigra after neuroleptic withdrawal. J Neurol Neurosurg Psychiatry 64:799-801. (Pubitemid 28274418)
23. Menza MA, Grossman N, Van Horn M, Cody R, and Forman N (1991) Smoking and movement disorders in psychiatric patients. Biol Psychiatry 30:109-115.
24. Millar NS and Gotti C (2009) Diversity of vertebrate nicotinic acetylcholine receptors. Neuropharmacology 56:237-246.
25. Nilsson A, Waller L, Rosengren A, Adlerberth A, and Wilhelmsen L (1997) Cigarette smoking is associated with abnormal involuntary movements in the general male population-a study of men born in 1933. Biol Psychiatry 41:717-723. (Pubitemid 27157763)
26. Picciotto MR and Zoli M (2008) Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease. Front Biosci 13:492-504. (Pubitemid 351599760)
27. Quik M, Cox H, Parameswaran N, O'Leary K, Langston JW, and Di Monte D (2007a) Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann Neurol 62:588-596.
28. Quik M, O'Neill M, and Perez XA (2007b) Nicotine neuroprotection against nigrostriatal damage: importance of the animal model. Trends Pharmacol Sci 28:229-235. (Pubitemid 46680334)
29. Quik M, Parameswaran N, McCallum SE, Bordia T, Bao S, McCormack A, Kim A, Tyndale RF, Langston JW, and Di Monte DA (2006) Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. J Neurochem 98:1866-1875. (Pubitemid 44313641)
30. Quik M, Perez XA, and Grady SR (2011) Role of α6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders. Biochem Pharmacol 82:873-882.
31. Quik M, Sum JD, Whiteaker P, McCallum SE, Marks MJ, Musachio J, McIntosh JM, Collins AC, and Grady SR (2003) Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice. Mol Pharmacol 63:1169-1179. (Pubitemid 36529935)
32. Quik M and Wonnacott S (2011) α6β2*and α4β2*Nicotinic acetylcholine receptors as drug targets for Parkinson's disease. Pharmacol Rev 63:938-966.
33. Reynolds KB, MacGillivray L, Zettler M, Rosebush PI, and Mazurek MF (2011) Role of the dopamine transporter in mediating the neuroleptic-induced reduction of tyrosine hydroxylase-immunoreactive midbrain neurons. Brain Res 1394:24-32.
34. Rogoza RM, Fairfax DF, Henry P, N-Marandi S, Khan RF, Gupta SK, and Mishra RK (2004) Electron spin resonance spectroscopy reveals alpha-phenyl-N-tertbutylnitrone spin-traps free radicals in rat striatum and prevents haloperidolinduced vacuous chewing movements in the rat model of human tardive dyskinesia. Synapse 54:156-163. (Pubitemid 39435345)
35. Saha S, Chant D, Welham J, and McGrath J (2005) A systematic review of the prevalence of schizophrenia. PLoS Med 2:e141.
36. Samaha AN, Reckless GE, Seeman P, Diwan M, Nobrega JN, and Kapur S (2008) Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biol Psychiatry 64:145-152.
37. Schleimer SB, Johnston GA, and Henderson JM (2005) Novel oral drug administration in an animal model of neuroleptic therapy. J Neurosci Methods 146:159-164. (Pubitemid 41373453)
38. Seeman P (2010) Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses 4:56-73.
39. Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ Jr, Okasha A, Singh B, Stein DJ, Olie JP, Fleischhacker WW, Moeller HJ, et al. (2008) World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 100:20-38.
40. Tarsy D, Lungu C, and Baldessarini RJ (2011) Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handb Clin Neurol 100:601-616.
41. Threlfell S and Cragg SJ (2011) Dopamine signaling in dorsal versus ventral striatum: the dynamic role of cholinergic interneurons. Front Syst Neurosci 5:11.
42. Turrone P, Remington G, Kapur S, and Nobrega JN (2003) The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats. Psychopharmacology (Berl) 165:166-171. (Pubitemid 36056993)
43. Turrone P, Remington G, and Nobrega JN (2002) The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy? Neurosci Biobehav Rev 26:361-380. (Pubitemid 34553319)
44. Volavka J and Citrome L (2009) Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother 10:1917-1928.
45. Waddington JL (1990) Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology (Berl) 101:431-447.
46. Yassa R, Lal S, Korpassy A, and Ally J (1987) Nicotine exposure and tardive dyskinesia. Biol Psychiatry 22:67-72. (Pubitemid 17229954)
47. Zhang XY, Yu YQ, Sun S, Zhang X, Li W, Xiu MH, Chen da C, Yang FD, Zhu F, Kosten TA, et al. (2011) Smoking and tardive dyskinesia in male patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 35:1765-1769.
48. Zhang Y, Xu H, He J, Yan B, Jiang W, Li X, and Li XM (2007) Quetiapine reverses altered locomotor activity and tyrosine hydroxylase immunoreactivity in rat caudate putamen following long-term haloperidol treatment. Neurosci Lett 420:66-71. (Pubitemid 46777105)